Literature DB >> 24905701

Genomic analysis and differential expression of HMG and S100A family in human arthritis: upregulated expression of chemokines, IL-8 and nitric oxide by HMGB1.

Ashok R Amin1, Abul B M M K Islam.   

Abstract

We applied global gene expression arrays, quantitative real-time PCR, immunostaining, and functional assays to untangle the role of High Mobility Groups proteins (HMGs) in human osteoarthritis (OA)-affected cartilage. Bioinformatics analysis showed increased mRNA expression of Damage-Associated Molecular Patterns (DAMPs): HMGA, HMGB, HMGN, SRY, LEF1, HMGB1, MMPs, and HMG/RAGE-interacting molecules (spondins and S100A4, S100A10, and S100A11) in human OA-affected cartilage as compared with normal cartilage. HMGB2 was down-regulated in human OA-affected cartilage. Immunohistological staining identified HMGB1 in chondrocytes in the superficial cartilage. Cells of the deep cartilage and subchondral bone showed increased expression of HMGB1 in OA-affected cartilage. HMGB1 was expressed in the nucleus, cytosol, and extracellular milieu of chondrocytes in cartilage. Furthermore, HMGB1 was spontaneously released from human OA-affected cartilage in ex vivo conditions. The effects of recombinant HMGB1 was tested on human cartilage and chondrocytes in vitro. HMGB1 stimulated mRNA of 2 NFκB gene enhancers (NFκB1 and NFκB2), 16 CC and CXC chemokines (IL-8, CCL2, CCL20, CCL3, CCL3L1, CCL3L3, CCL4, CCL4L1, CCL4L2, CCL5, CCL8, CXCL1, CXCL10, CXCL2, CXCL3, and CXCL6) by ≥10-fold. Furthermore, HMGB1 and IL-1β and/or tumor necrosis factor α (but not HMGI/Y) also significantly induced inducible nitric oxide synthase, NO, and interleukin (IL)-8 production in human cartilage and chondrocytes. The recombinant HMGB1 utilized in this study shows properties that are similar to disulfide-HMGB1. The differential, stage and/or tissue-specific expression of HMGB1, HMGB2, and S100A in cartilage was associated with regions of pathology and/or cartilage homeostasis in human OA-affected cartilage. Noteworthy similarities in the expression of mouse and human HMGB1 and HMGB2 were conserved in normal and arthritis-affected cartilage. The multifunctional forms of HMGB1 and S100A could perpetuate damage-induced cartilage inflammation in late-stage OA-affected joints similar to sterile inflammation. The paracrine effects of HMGB1 can induce chemokines and NO that are perceived to change cartilage homeostasis in human OA-affected cartilage.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24905701      PMCID: PMC4117271          DOI: 10.1089/dna.2013.2198

Source DB:  PubMed          Journal:  DNA Cell Biol        ISSN: 1044-5498            Impact factor:   3.311


  104 in total

Review 1.  New EMBO members' review: the double life of HMGB1 chromatin protein: architectural factor and extracellular signal.

Authors:  S Müller; P Scaffidi; B Degryse; T Bonaldi; L Ronfani; A Agresti; M Beltrame; M E Bianchi
Journal:  EMBO J       Date:  2001-08-15       Impact factor: 11.598

Review 2.  HMGB1: a multifunctional alarmin driving autoimmune and inflammatory disease.

Authors:  Helena Erlandsson Harris; Ulf Andersson; David S Pisetsky
Journal:  Nat Rev Rheumatol       Date:  2012-01-31       Impact factor: 20.543

Review 3.  NF-κB, the first quarter-century: remarkable progress and outstanding questions.

Authors:  Matthew S Hayden; Sankar Ghosh
Journal:  Genes Dev       Date:  2012-02-01       Impact factor: 11.361

Review 4.  Distinct roles of Sox5, Sox6, and Sox9 in different stages of chondrogenic differentiation.

Authors:  Toshiyuki Ikeda; Hiroshi Kawaguchi; Satoru Kamekura; Naoshi Ogata; Yoshiyuki Mori; Kozo Nakamura; Shiro Ikegawa; Ung-il Chung
Journal:  J Bone Miner Metab       Date:  2005       Impact factor: 2.626

5.  Osteoarthritis cartilage histopathology: grading and staging.

Authors:  K P H Pritzker; S Gay; S A Jimenez; K Ostergaard; J-P Pelletier; P A Revell; D Salter; W B van den Berg
Journal:  Osteoarthritis Cartilage       Date:  2005-10-19       Impact factor: 6.576

6.  STR/ort mice, a model for spontaneous osteoarthritis, exhibit elevated levels of both local and systemic inflammatory markers.

Authors:  Sirkka Kyostio-Moore; Bindu Nambiar; Elizabeth Hutto; Patty J Ewing; Susan Piraino; Patricia Berthelette; Cathleen Sookdeo; Gloria Matthews; Donna Armentano
Journal:  Comp Med       Date:  2011-08       Impact factor: 0.982

Review 7.  HMGB1 and RAGE in inflammation and cancer.

Authors:  Gary P Sims; Daniel C Rowe; Svend T Rietdijk; Ronald Herbst; Anthony J Coyle
Journal:  Annu Rev Immunol       Date:  2010       Impact factor: 28.527

8.  CCL20/CCR6 chemokine/receptor expression in bone tissue from osteoarthritis and rheumatoid arthritis patients: different response of osteoblasts in the two groups.

Authors:  Gina Lisignoli; Cristina Manferdini; Katia Codeluppi; Anna Piacentini; Francesco Grassi; Luca Cattini; Giuseppe Filardo; Andrea Facchini
Journal:  J Cell Physiol       Date:  2009-10       Impact factor: 6.384

Review 9.  HMGB1 is a potent trigger of arthritis.

Authors:  U Andersson; H Erlandsson-Harris
Journal:  J Intern Med       Date:  2004-03       Impact factor: 8.989

10.  Human osteoclasts express different CXC chemokines depending on cell culture substrate: molecular and immunocytochemical evidence of high levels of CXCL10 and CXCL12.

Authors:  Francesco Grassi; Anna Piacentini; Sandra Cristino; Stefania Toneguzzi; Carola Cavallo; Andrea Facchini; Gina Lisignoli
Journal:  Histochem Cell Biol       Date:  2003-11-05       Impact factor: 4.304

View more
  20 in total

Review 1.  The danger from within: alarmins in arthritis.

Authors:  Meriam Nefla; Dirk Holzinger; Francis Berenbaum; Claire Jacques
Journal:  Nat Rev Rheumatol       Date:  2016-10-13       Impact factor: 20.543

Review 2.  HMGB proteins and arthritis.

Authors:  Noboru Taniguchi; Yasuhiko Kawakami; Ikuro Maruyama; Martin Lotz
Journal:  Hum Cell       Date:  2017-09-15       Impact factor: 4.174

Review 3.  Inflammation in osteoarthritis: is it time to dampen the alarm(in) in this debilitating disease?

Authors:  M H J van den Bosch
Journal:  Clin Exp Immunol       Date:  2018-11-28       Impact factor: 4.330

Review 4.  Chemokines and inflammation in osteoarthritis: Insights from patients and animal models.

Authors:  Carla R Scanzello
Journal:  J Orthop Res       Date:  2017-03-08       Impact factor: 3.494

5.  CXCL10 is upregulated in synovium and cartilage following articular fracture.

Authors:  Bridgette D Furman; Collin L Kent; Janet L Huebner; Virginia B Kraus; Amy L McNulty; Farshid Guilak; Steven A Olson
Journal:  J Orthop Res       Date:  2017-11-20       Impact factor: 3.494

6.  ABCF1 extrinsically regulates retinal pigment epithelial cell phagocytosis.

Authors:  Feiye Guo; Ying Ding; Nora Caberoy; Gabriela Alvarado; Feng Wang; Rui Chen; Wei Li
Journal:  Mol Biol Cell       Date:  2015-04-22       Impact factor: 4.138

7.  Genomic, Lipidomic and Metabolomic Analysis of Cyclooxygenase-null Cells: Eicosanoid Storm, Cross Talk, and Compensation by COX-1.

Authors:  Abul B M M K Islam; Mandar Dave; Sonia Amin; Roderick V Jensen; Ashok R Amin
Journal:  Genomics Proteomics Bioinformatics       Date:  2016-03-21       Impact factor: 7.691

8.  DAMPs Synergize with Cytokines or Fibronectin Fragment on Inducing Chondrolysis but Lose Effect When Acting Alone.

Authors:  Lei Ding; Joseph A Buckwalter; James A Martin
Journal:  Mediators Inflamm       Date:  2017-07-18       Impact factor: 4.711

Review 9.  Emerging Players at the Intersection of Chondrocyte Loss of Maturational Arrest, Oxidative Stress, Senescence and Low-Grade Inflammation in Osteoarthritis.

Authors:  Manuela Minguzzi; Silvia Cetrullo; Stefania D'Adamo; Ylenia Silvestri; Flavio Flamigni; Rosa Maria Borzì
Journal:  Oxid Med Cell Longev       Date:  2018-02-11       Impact factor: 6.543

10.  Calgizzarin (S100A11): a novel inflammatory mediator associated with disease activity of rheumatoid arthritis.

Authors:  Lucie Andrés Cerezo; Barbora Šumová; Klára Prajzlerová; David Veigl; Dres Damgaard; Claus Henrik Nielsen; Karel Pavelka; Jiří Vencovský; Ladislav Šenolt
Journal:  Arthritis Res Ther       Date:  2017-04-26       Impact factor: 5.156

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.